BR112018001564A2 - sistema de entrega transdérmica - Google Patents

sistema de entrega transdérmica

Info

Publication number
BR112018001564A2
BR112018001564A2 BR112018001564A BR112018001564A BR112018001564A2 BR 112018001564 A2 BR112018001564 A2 BR 112018001564A2 BR 112018001564 A BR112018001564 A BR 112018001564A BR 112018001564 A BR112018001564 A BR 112018001564A BR 112018001564 A2 BR112018001564 A2 BR 112018001564A2
Authority
BR
Brazil
Prior art keywords
delivery system
transdermal delivery
dihydroetorphine
hydrate
meth
Prior art date
Application number
BR112018001564A
Other languages
English (en)
Portuguese (pt)
Inventor
Phyllis Harding Deborah
Mundin Gill
Johnson Helen
Smith Kevin
Whitelock Steve
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR112018001564A2 publication Critical patent/BR112018001564A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018001564A 2015-07-30 2016-07-28 sistema de entrega transdérmica BR112018001564A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1513442.2A GB201513442D0 (en) 2015-07-30 2015-07-30 Transdermal patch
PCT/GB2016/052308 WO2017017453A1 (en) 2015-07-30 2016-07-28 Transdermal delivery system

Publications (1)

Publication Number Publication Date
BR112018001564A2 true BR112018001564A2 (pt) 2018-09-18

Family

ID=54062903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001564A BR112018001564A2 (pt) 2015-07-30 2016-07-28 sistema de entrega transdérmica

Country Status (16)

Country Link
US (1) US20180221298A1 (https=)
EP (1) EP3328432A1 (https=)
JP (1) JP6793718B2 (https=)
KR (1) KR20180031039A (https=)
CN (1) CN108136028A (https=)
AR (1) AR105534A1 (https=)
AU (1) AU2016298762A1 (https=)
BR (1) BR112018001564A2 (https=)
CA (1) CA2994109A1 (https=)
GB (1) GB201513442D0 (https=)
IL (1) IL256994A (https=)
MA (1) MA42522A (https=)
MX (1) MX2018001320A (https=)
SG (1) SG10201913253TA (https=)
TW (1) TW201707693A (https=)
WO (1) WO2017017453A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10231248A (ja) * 1997-02-19 1998-09-02 T T S Gijutsu Kenkyusho:Kk ジヒドロエトルフィン含有経皮吸収型製剤
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CN1780611B (zh) * 2003-04-30 2013-01-30 珀杜医药公司 包括活性剂部分以及在活性剂层远侧的逆转剂的抗改造透皮剂型
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
DE102005011517A1 (de) * 2005-03-10 2006-09-21 Grünenthal GmbH Transdermales therapeutisches System zur Verabreichung von Analgetika
TWI541246B (zh) * 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) * 2013-05-30 2013-07-17 Euro Celtique Sa Method

Also Published As

Publication number Publication date
JP2018528176A (ja) 2018-09-27
MA42522A (fr) 2018-06-06
MX2018001320A (es) 2018-08-15
SG10201913253TA (en) 2020-03-30
JP6793718B2 (ja) 2020-12-02
KR20180031039A (ko) 2018-03-27
TW201707693A (zh) 2017-03-01
EP3328432A1 (en) 2018-06-06
WO2017017453A1 (en) 2017-02-02
US20180221298A1 (en) 2018-08-09
AR105534A1 (es) 2017-10-11
GB201513442D0 (en) 2015-09-16
CN108136028A (zh) 2018-06-08
AU2016298762A1 (en) 2018-02-15
CA2994109A1 (en) 2017-02-02
IL256994A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
IL263513A (en) Improved adoptive t-cell therapy
EP3297620A4 (en) TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
IL272278A (en) Local disinfection for drug delivery system
EP3294398A4 (en) SYSTEM AND METHOD FOR THE ADMINISTRATION OF MEDICAMENTS
EP3397250C0 (en) LONG-TERM TRANSDERMAL DELIVERY SYSTEMS
EP3664885A4 (en) TRANSDERMAL DRUG DELIVERY SYSTEM
EP3313499A4 (en) DEVICES, SYSTEMS AND METHODS FOR INCREASING THE INTRALUMINAL DRUG DELIVERY AND RECEIVING
PL3928763T3 (pl) Przezśluzówkowe i przezskórne systemy dostarczania
WO2014153030A3 (en) Methods of treating cancer and preventing cancer drug resistance
BR112017020735A2 (pt) sistema de tratamento com inicialização por pressão de aparelho de infusão
EP3581183A4 (en) PHARMACEUTICAL COMPOSITION FOR ONCOTHERAPY
EP3349737A4 (en) SYSTEM FOR TRANSDERING
DK3310800T3 (da) Leveringssystem til styret lægemiddelfrigivelse
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
ZA202007757B (en) Localised transdermal iontophoretic drug delivery system
EP3096745A4 (en) Transdermal delivery system comprising donepezil or its salt
EP3377011A4 (en) LASER-ASSISTED MEDICAMENT DELIVERY SYSTEM
DK3549374T3 (da) Kommunikations- og sporingssystem til lægemiddelindgiftsanordninger til engangsbrug
EP3164412A4 (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
BR112017024039B8 (pt) Piroglutamato de vortioxetina, composições farmacêuticas e gel compreendendo o mesmo, método para preparar um gel, e usos do piroglutamato de vortioxetina para fabricação de um medicamento ou gel
EP3381472A4 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF
EP3267982A4 (en) Fentanyl transdermal delivery system
BR112017020404A2 (pt) medicamento
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2630 DE 01-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.